Broad-Spectrum Profiling of Drug Safety via Learning Complex Network. by Liu Ke et al.
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/cpt.1750
 This article is protected by copyright. All rights reserved
Broad-Spectrum Profiling of Drug Safety via Learning Complex Network
Ke Liu1#, Ruo-Fan Ding1#, Han Xu3, Yang-Mei Qin1, Qiu-Shun He1, Fei Du1, Yun Zhang1, Li-Xia 
Yao4, Pan You5, Yan-Ping Xiang3, and Zhi-Liang Ji1,2
1State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, 
Xiamen, Fujian, 361102, P R China
2The Key Laboratory for Chemical Biology of Fujian Province, Xiamen University, Xiamen, 
Fujian, 361005, P R China
3School of Computer Science and Engineering, University of Electronic Science and Technology 
of China, Chengdu, Sichuan, 610054, P R China
4Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
5Xiamen Xianyue Hospital, Xiamen, Fujian, 361012, P R China
# These authors contributed equally to this work
Correspondence: Zhi-Liang Ji, Ph.D., Program Director, No. 4221-120, Xiang’an South Road, 
Xiang'an Distric, Xiamen, Fujian, China, Phone: 0592-2182897, appo@xmu.edu.cn.
Conflicts of Interest: All authors declared no competing interests for this work.
Funding: This work was supported by the National Natural Science Foundation of China [grant 
number 31671362 and 31271405].
Keywords: Safety, Adverse Drug Reactions, Mathematical modeling, computational biology, 
network analysis, systems pharmacology
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Abstract
Drug safety is a severe clinical pharmacology and toxicology problem that has caused immense 
medical and social burdens every year. Regretfully, there still misses a reproducible method to 
assess drug safety systematically and quantitatively. In this study, we developed an advanced 
machine learning model for de novo drug safety assessment by solving the multilayer 
drug-gene-adverse drug reaction (ADR) interaction network. For the first time, the drug safety was 
assessed in a broad landscape of 1,156 distinct ADRs. We also designed a parameter 
ToxicityScore to quantify the overall drug safety. Moreover, we determined association strength 
for every 3,807,631 gene-ADR interactions, which clues mechanistic exploration of ADRs. For 
convenience, we deployed the model as a web service ADRAlert-gene at 
http://www.bio-add.org/ADRAlert/. In summary, this study offers insights into prioritizing safe 
drug therapy. It helps to reduce the attrition rate of new drug discovery by providing reliable ADR 
profile in early pre-clinical stage. 
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Introduction
Drug safety is a severe clinical problem in drug therapy. It has caused immense medical and social 
burdens around the world every year. Drug safety research answers why a particular drug causes 
side effects or adverse drug reactions (ADRs) in a particular patient. The World Health 
Organization (WHO) defines ADR as "responses to a medicine which is noxious and unintended, 
and which occurs at doses normally used in man". Severe ADRs (SADRs) often lead to 
hospitalization, prolonged hospital staying, increased cost of care, disability, and even death (1-3). 
It was reported that fatal ADRs answered for more than 100,000 deaths in U.S. hospitals in 1994 
(4). The ADR-related mortality increased significantly over time at a rate of 0.58% per year since 
1999 (5). Besides, ADRs accounted for about 24% of all failures in clinical trials of new drug 
discovery, second to unsatisfied efficacy (6). Therefore, it is extremely important to monitor and 
assess drug safety throughout the life cycle of drug development, from early drug discovery to 
post-market surveillance (7). 
Conventionally, both in vitro and in vivo tests are undertaken before clinical trials to help rapidly 
remove out those highly toxic drugs. Be that as it may, more than 20% of drug candidates still 
failed in clinical trials due to their poor toxicity profiles (8). Regretfully, the toxicity information 
collected from cell experiments like MTT assays and animal studies cannot be fully transferred to 
human if they are not interpreted prudently. More reliable ADR profiles are usually created in 
clinical trials among small but carefully recruited patient population and from large-scale 
post-market surveillance, which is costly and time-consuming. Sometimes, it has to compromise 
patients' treatment and satisfaction. For all this, the ADR profiles present in the drug labels can 
still be incomplete or inaccurate due to the medical complexity (9). 
As a complementary solution to experimental assays, computational methods have been developed 
for drug toxicity evaluation. For instance, a number of computer programs built upon the 
quantitative structure-activity relationship (QSAR) for high throughput assessment of drug toxicity 
such as hepatotoxicity, nephrotoxicity, genotoxicity, oncogenicity, and so on. Typical applications 
include DEREK (10), TOPKAT (11), COMPACT (12), MULTICASE (13), HazardExpert (14), 
and OncoLogic. It is noteworthy that drug toxicity and ADR are two linked but different concepts. A
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Drug toxicity is often determined under different medication dosing and timing to assess 
damaging effects of definite chemical on cells or organs at early drug discovery stage; while the 
ADRs are undesired clinical consequences observed in drug therapy. However, the chemical 
structure itself possesses some hidden features to cause cell/organ toxicity and eventually induce 
ADRs. Hence, linking chemical features to ADRs provide a feasible way to aid better 
investigation of ADRs (15). Some machine learning algorithms like decision tree have been 
applied to determine the chemical, physical, and structural properties of chemical drugs that 
predispose to ADRs (16-18). 
In a view of systems biology, the interactions between drug (or its metabolites) and proteins or 
pathways are likely the driving force to drug-induced adverse events. In recent years, different 
research groups tried to depict ADRs by undesired drug-protein interactions, perturbation of 
metabolic pathways, or organ malfunction (19). For instance, the SePreSA built chemical-protein 
interactome to predict serious ADRs (20). LaBute et al. used logistic regression models on top of 
molecular docking for ADR prediction (21). Huang et al. proposed a framework for predicting 
ADR profiles by integrating protein-protein interaction (PPI) networks with drug structures (22). 
Liu et al. combined chemical structures, biological properties and phenotypic characteristics of 
drugs for ADR prediction using machine learning method (23). Cami et al. developed the 
predictive pharmacosafety networks (PPNs) that combined the safety, taxonomic, and biological 
information of specific drugs and adverse events (24). Pan et al. used a high-throughput docking 
program to create proteome-wide drug-off-target interaction profiles for network understanding of 
severe ADRs (25). It was proposed that target/pathway-based methods might outperform 
ligand-based methods in ADR assessment as they circumvented the hurdle of linking drug itself or 
its metabolites to specific ADRs (26). However, the full drug-target interaction profiles are usually 
hard to be obtained by current experimental and computational technologies. Although high 
throughput screening systems can make use of robotics to test, automatically and quickly, the 
interaction activities between drugs and protein targets; the screening is usually limited to some 
well-established protein panels like kinases and receptors. As the result, the target-based ADR 
studies often demonstrated on several ADRs of interest. A
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Recent advance in systems pharmacology and toxicology incorporate microarray and next 
generation-sequencing (NGS) to monitor large-scale gene expression changes in response to 
outside chemical stimulus simultaneously. By comparison of gene expression profiles in different 
cell lines, drug efficacies to different tumor therapies can be evaluated (27). This inspires us the 
opportunity to directly link biological effects (i.e., gene expression changes) to clinical outcomes 
(i.e., ADRs) upon drug treatment (19), leaving the intermediate drug-target/pathway interactions 
as a black box. Such kind of strategy will take advantages of systems biology in network depiction 
of ADRs and at the same time bypass the difficulty in acquiring full profile of drug-target 
interactions underlying ADRs. In this study, we will construct a multilayer complex 
drug-gene-ADR interaction network by integrating heterogeneous, multiscale, and historical data. 
Upon the network, we aim to develop an advanced machine learning model for de novo ADR 
prediction, via building the full spectrum of gene-ADR associations statistically in a retrospective 
manner. At last, we will try to use the weighted gene-ADR associations in unveiling ADR 
mechanisms systematically.  
Materials and Methods
The hypothesis
In this study, we built a model on top of a multilayer drug-gene-ADR complex network (Figure 3) 
according to the assumption as followings: As the clinical consequence of drug treatment, ADRs 
sometimes occur. The occurrence of ADRs could attribute to any one or combination of 
mechanisms such as overdose, weak pharmacokinetic, drug-drug interaction, off target, and so on. 
Underlying these mechanisms are cascade molecular events lead by drug treatment, including 
abnormal protein activity, disturbance of biological pathway, and dysfunction of organs. 
Regretfully, it is hard to determine the driving molecular events and their subsequent ADR 
mechanisms in most cases. However, when receiving drug treatment, genes also change their 
expressions as the biological outcome resulting of whatever protein or pathway disturbance. In 
particular, the gene expressions mostly change at the focus tissues where ADRs happen. Hence, 
the significant gene expression changes have sort of associations with the ADRs. Compared to the A
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hard-to-acquire drug-protein interactions, the drug-gene interactions are easy to be determined, 
thanks for the wide application of transcriptome technologies. Then, the problem is a shift to 
building the logic associations between gene expression changes and ADRs. Taking advantages of 
machine learning, we can determine the association strength for every gene-ADR pairs via 
statistically solving the known drug-gene-ADR relations (Figure 3). By doing so, we bypass the 
complex molecular interaction mechanisms underlying ADR and leave the exact molecular 
mechanisms as a black box in advance. When the gene-ADR associations are substantially 
represented and measured in the model, evaluation of ADR profile from the drug-regulated genes 
becomes feasible. 
Data sources and data processing
To build the model, we incorporated a number of relations in the multilayer interaction network 
from various sources, including drug-ADR relations, drug-gene regulations, gene-gene 
interactions, ADR concurrence, and so on.
Drug-ADR relations. We derived the drug-ADR relations from the Adverse Drug Reaction 
Classification System (ADReCS version 1.4, http://bioinf.xmu.edu.cn/ADReCS) (28). The 
ADReCS is a comprehensive ADR ontology database that offers both standardization and 
hierarchical classification of ADR terms via integrating the information from multiple resources 
such as MedDRA(29), WHO-ART(30), DailyMed, and SIDER2 (31). The ADReCS 1.4 covers 
total 6,778 standard ADR terms, 1,378 marketed drugs and 196,194 non-redundant drug-ADR 
pairs from the drug labels. However, subject to the availability of known drug-gene relations, 
current model only included 365 drugs and 1,156 ADR High Level Terms (HLTs). In MedDRA 
and ADReCS, each HLT represents a group of related ADRs in basis of anatomy, pathology, 
physiology, etiology or function.
Drug-gene relations. We derived 106,739 literature-documented human drug-gene relations from 
the Comparative Toxicogenomics Database (CTD, http://ctdbase.org)  (32). The direction and 
strength of drug-gene regulations were downloaded when available. As a complementary source, 
we also extracted the drug-gene relations from the Library of Integrated Network-based Cellular 
Signatures (LINCS, http://www.lincsproject.org)  (33-35). The LINCS was elaborately designed A
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to determine how perturbations like drug treatment affect gene expressions across multiple cells 
and perturbation types (36). In this study, we obtained normalized gene expression profiles 
(Z-score) from 14 cell line experiments treated with drugs at a concentration of 10 μM for 6 hours. 
The selection of experimental conditions was in consideration of acquiring as more as possible 
drug-gene relations under the constraints of data availability. For each drug treatment, 
differentially expressed genes, comparing to the untreated control, with the moderated Z-scores >= 
2 or Z-scores <= -2 over at least two experiments were taken as reliable signature genes for the 
drug (i.e., drug-regulated genes). For modeling, we only adopted the consensus drug-gene pairs 
that had the same regulation direction (up-regulation or down-regulation) in all experiments. To 
weight the regulation strength for a consensus drug-gene regulation pair, we selected either the 
maximum positive value of Z-scores for up-regulation or the minimum negative value of Z-scores 
for down-regulation in all experiments. Ultimately, we obtained 25,274 drug-gene relations form 
the LINCS. Compared to the CTD, the drug-gene relations mined from the LINCS are 
comparatively full-scale than those from scientific literature or individual experiments deposited 
in ArrayExpress (37) and Gene Expression Omnibus (GEO) (38). The inclusion of LINCS data 
may improve the integrity and reliability of the drug-gene-ADR trilateral network.
Gene-gene relations. We obtained the quantitative gene-gene relations from the GeneMANIA 
Cytoscape plugin (39). GeneMANIA measures gene-gene relations using a guilt-by-association 
approach over publicly available biological big data. The big data include multiple molecule 
interaction networks of protein-protein, protein-DNA, genetic interaction, pathway, co-expression, 
co-localization, and protein domain similarity from multiple organisms (40, 41). In this study, we 
measured the gene-gene relations quantitatively with all Homo sapiens interaction networks and 
incorporated those relations with weight >= 0.001 into the model.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
ADR-ADR concurrence. The information ADR concurrence was determined in the basis of the 
ADReCS data. We calculated the concurrence rate, denoted as w, between a pair of ADR HLTs – 
Aa (consisting of x Preferred Terms) and Ab (consisting of y Preferred 
Terms) by:
, (1)𝑤𝑃𝑇𝑎𝑃𝑇𝑏 =
𝐷𝑃𝑇𝑎 ∩ 𝑃𝑇𝑏
𝐷𝑃𝑇𝑎 ∪ 𝑃𝑇𝑏
×
𝐷𝑃𝑇𝑎 × 𝐷𝑃𝑇𝑏
𝐷2A
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, (2)𝑤𝐴𝑎𝐴𝑏 =
∑𝑥,𝑦
𝑖 = 1,𝑗 = 1𝑤𝑃𝑇𝑖𝑃𝑇𝑗 × (𝐷𝑃𝑇𝑖𝐷𝐴𝑎 +
𝐷𝑃𝑇𝑗
𝐷𝐴𝑏
)
∑𝑥,𝑦
𝑖 = 1,𝑗 = 1(𝐷𝑃𝑇𝑖𝐷𝐴𝑎 +
𝐷𝑃𝑇𝑗
𝐷𝐴𝑏
)
where DAa stands for the number of drugs inducing Aa, DAb stands for the number of drugs 
inducing Ab, DPTi stands for the number of drugs inducing Preferred Term PTi of Aa, DPTj stands 
for the number of drugs inducing PTj of Ab, DPTi∩PTj stands for the number of drugs inducing both 
PTi and PTj, DPTi∪PTj stands for the number of drugs inducing either PTi or PTj, and D stands for 
the total number of drugs in the model. Only ADR-ADR pairs with concurrency >= 0.01 were 
used in the model.
Eventually, we built the model using 38,761 drug-ADR relations, 20,867 drug-gene relations, 
19,229 gene-gene interactions, 6,195 ADR-ADR pairs, 365 drugs, 8,571 genes, and 1,156 distinct 
ADR HLTs.
Construction of the machine learning model
The weighted Bayesian model 
We denoted the three partners of drug-gene-ADR complex network as the drug set D = {D1, D2, 
…, Dl}, the gene set G = {G1, G2, …, Gn}, and the ADR set A = {A1, A2, …, Am}. In the trilateral 
relationship, we assume that a drug in D may induce multiple ADRs in A; and vice versa, an ADR 
in A may be induced by multiple drugs in D. At the meantime, a drug in D may regulate multiple 
genes in G; and vice versa, a gene in G may be regulated by multiple drugs in D.
In previous work, we constructed an unweighted naïve Bayesian model prototype (42) for ADR 
prediction, assuming that the drug-gene-ADR trilateral relations were all independent, 
unweighted, and directionless. Such an assumption is too idealized that all elements in the 
molecular network are cross-interacted in the real world. Therefore, we significantly improved the 
model as followings in this study.
In the case of ADR induced by expression change of single gene Gn (Gn  G), the drug set that 
regulates Gn (i.e., the drug-gene pairs) were denoted as DGn = {D1, D2, …, Dq} (DGn  D). The 
drug set that regulates Gn and thus leads to ADR Am (Am  A) was denoted as DGnAm = {D1, D2, …, 
Dp} (DGnAm  DGn). Accordingly, the posterior probability of Am induced by expression change of A
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single gene Gn (despite of gene-gene regulation and ADR concurrence), denoted as P(Am|Gn), can 
be calculated by:
, (3)𝑃(𝐴𝑚|𝐺𝑛) =
∑𝑝
𝑖 = 1𝑤𝐷𝑖𝐺𝑛 × 𝑤𝐷𝑖𝐴𝑚
∑𝑞
𝑗 = 1𝑤𝐷𝑗𝐺𝑛 × 𝑤𝐷𝑗𝐴
where wDiGn stands for the regulation strength of drug Di (Di  DGnAm) on gene Gn which was 
described in above section, wDiAm stands for the frequency of ADR Am in drug Di treatment, wDjGn 
stands for the regulation strength of Dj (Dj  DGn) on Gn, wDjA stands for the frequency of any 
ADR  A in Dj treatment.
In the real world, an ADR can be induced by expression changes of multiple genes, denoted as 
gene set Gtgt = {G1, G2, …, Gt} (Gtgt  G and Gn  Gtgt). As the result, the probability of Am 
triggered by Gtgt, denoted as P(Am|Gtgt), can be calculated by:
, (4)𝑃(𝐴𝑚|𝐺𝑡𝑔𝑡) = 1 ― ∏
𝑡
𝑛 = 1(1 ― 𝑃(𝐴𝑚|𝐺𝑛)′)
where P(Am|Gn)’ stands for the probability of Am triggered by Gn. 
Incorporation of gene-gene regulation and ADR concurrence. 
In the real world, genes have interactions between each other, and ADRs often happen together. 
We denoted the genes that interact with Gn as Gcon = {G1, G2, …, Gs} (Gcon  G and Gn  Gcon). 
As well, we denoted the ADRs that occur concurrently with Am as Acon = {A1, A2, …, Ar} (Acon  A 
and Am  Acon). When incorporating the gene-gene regulation and ADR concurrence into the 
model, the probability of Am triggered by gene set Gtgt, denoted as P(Am|Gtgt), can be calculated by:
, (5)𝑃(𝐴𝑚|𝐺𝑡𝑔𝑡) = 1 ― ∏
𝑠,𝑟
𝑖 = 1,𝑗 = 1(1 ― 𝑤𝐺𝑛𝐺𝑖 × 𝑃(𝐴𝑗|𝐺𝑖)′ × 𝑤𝐴𝑚𝐴𝑗)
where wGnGi stands for the weight of Gn-Gi interaction (Gi  Gcon), wAmAj stands for the weight of 
Am-Aj concurrence (Aj  Acon), and P(Aj|Gi)’ stands for the probability of Aj triggered by Gi. The 
probability P(Am|Gtgt) can also be taken as the estimated frequency or occurrence of ADR Am.
Normalization of ADR probability by adjusting the bias caused by drug-gene regulations. 
As our observation, the estimated frequency was affected by the number of effective input genes. 
Hence, we demonstrated a retrospective ADR prediction for 324 drugs, analyzing the change of 
detection rates (DRs) and false positive rates (FPRs) by the number of input genes, ranging from 1 A
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to 25. The results suggested three or more effective genes could yield an average DR of >= 70% 
by the estimated frequency threshold of 1%. The more the effective input genes, the higher the 
average DR and as well as higher FPR (Figure 4). Therefore, to eliminate the bias caused by the 
number of input genes and at the same time normalize the estimated ADR frequency into the same 
scale of the observed ADR occurrence rate, we made an empirical correction of estimated 
frequency P(Am|Gtgt) to a normalized value, denoted as P(Am|Gtgt)norm, which can be determined by:
 𝑃(𝐴𝑚|𝐺𝑡𝑔𝑡)𝑛𝑜𝑟𝑚 = 1 ― ∏
𝑡
𝑘 = 1(1 ― 3 + [𝑡 /10]𝑡 × 𝑃(𝐴𝑚|𝐺𝑘)′)if (3 <=  t <  100),
 𝑃(𝐴𝑚|𝐺𝑡𝑔𝑡)𝑛𝑜𝑟𝑚 = 1 ― ∏
𝑡
𝑘 = 1(1 ― 12 + [𝑡 /100]𝑡 × 𝑃(𝐴𝑚|𝐺𝑘)′)if (100 <=  t <  1000),
(6)𝑃(𝐴𝑚|𝐺𝑡𝑔𝑡)𝑛𝑜𝑟𝑚 = 1 ― ∏
𝑡
𝑘 = 1(1 ― 21 + [𝑡 /1000]𝑡 × 𝑃(𝐴𝑚|𝐺𝑘)′)if (t >=  1000),
where t stands for the number of effective input genes for ADR assessment.
Model evaluation
In this study, we adopted the conventional 10-fold cross-validation strategy to evaluate model 
performance in basis of 365 marketed drugs. All the drugs were randomly divided into 10 folds 
(subsamples) of nearly equal size, every of which had similar data distribution in 14 ATC 
categories (Supplementary Figure S1). For the 10 folds, nine were used for model training and 
one was retained as the validation dataset for model testing. The cross-validation process was 
repeated 10 times, which each of the 10 folds was chosen as the validation data once. We also 
derived 18 external trial drugs extracted from the ClinicalTrials database (http://clinicaltrials.gov) 
by the criteria of: 1) the trial drugs are not recorded in both ADReCS database and DrugBank 
database, and 2) the drugs have information of at least three drug-gene regulations. Unlike most 
deterministic methods that make the true or false classification, the Bayesian model of this study 
outputs the probability for every ADRs in a broad spectrum of 1,156 distinct ADR HLTs. 
Therefore, we adopted the detection rate (DR) to measure the ratio of known ADRs predicted by 
the model:
, (7)𝐷𝑅 =
𝑃𝐾𝐴
𝐾𝐴 × 100%
where PKA stands for the number of known ADRs predicted by the model and KA stands for the 
number of known ADRs. In addition, we also adopted metrics like accuracy, sensitivity, A
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specificity, the receiver operating characteristic curve (ROC), and the area under the curve of ROC 
(AUC) for model evaluation.
The ToxicityScore for summarizing drug safety
In this study, we introduced a new parameter, the ToxicityScore, to summarize the toxicity effects 
of a drug. This parameter evaluates the overall drug safety by integrating the information of both 
ADR occurrence rate (here, the estimated ADR frequency) and ADR severity. The ToxicityScore 
overcome the shortages of current methods that relied on several preset toxicity features like 
hepatic toxicity and kidney toxicity for drug safety assessment in early drug discovery. In advance, 
we pre-assigned ADRs into five severity categories of mild, moderate, severe, life-threatening or 
death according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 
4.0(43, 44). The CTCAE is a predominant system for describing the severity of adverse events 
(AEs) commonly encountered in clinical trials. Here, we determined severity grade for each ADR 
HLT used in the model manually according to the guideline of CTCAE. As each HLT may consist 
of multiple ADR PTs of different severity grades, we adopted the lowest grade of the most 
frequent PT induced by most drugs as the grade for HLT. Examples of ADR severity assignment 
were given in Table S1. To quantitatively differentiate the grades, we further assigned ADR a 
severity score Si of 1, 10, 100, 1000, and 10000 for grade 1 to 5, respectively.
The ToxicityScore can be determined by:
, (8)𝑇𝑜𝑥𝑖𝑐𝑖𝑡𝑦𝑆𝑐𝑜𝑟𝑒 = ∑
𝑛
𝑖 = 1(𝐹𝑖𝑆𝑖)
2 = (𝐹1𝑆1)2 + (𝐹2𝑆2)2 + ... + (𝐹𝑛𝑆𝑛)2
where Fi stands for the estimated/observed occurrence rate of ADR Ai, Si stands for the severity 
score of ADR Ai, and Ai belongs to ADR list A {A1, A2, …, An} of the drug. The estimated 
frequency Fi comes from the model prediction. 
Results
The performance of the advanced machine learning model
According to conventional practice, we evaluated the model performance using both internal 
dataset and external dataset. The internal 10-fold cross-validation yielded an average detection rate A
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(DR) of 91.70% if all predicted ADRs were included (frequency threshold>0) (Table 1). When 
setting the ADR frequency threshold to 0.1%, a frequency threshold of “less common ADRs” 
defined by Wooten (45), the average DR dropped to 75.10%. The drop of DR was the result of 
excluding the rare known ADRs with occurrence rate <0.1%. At the same time, the threshold also 
helped eliminating about 65.26% of potential false positives (newly predicted ADRs). The 
independent test was undertaken on 18 external real-world trial drugs extracted from the 
ClinicalTrials database, which yielded an average DR of 98.22% or 84.38% (estimated occurrence 
rate >=0.1%). In addition, we also evaluated the model performance using several metrics that are 
often adopted in evaluating deterministic models. In general, the model achieved an accuracy of 
81.11% and 75.59% for internal and external dataset at the frequency threshold of 0.1%, 
respectively; accordingly, the AUC value was 78.91% and 79.85%, respectively (Table 1). Be 
noted, these metrics were under-estimated due to excluding the rare ADRs (estimated frequency 
<0.1%), which are usually counted in reality. Hence, both the internal and external evaluation 
consolidated the model robust in ADR prediction.
The web service of ADRAlert-gene for rapid drug safety profiling
For user convenience, we deployed the well-established model as a web service ADRAlert-gene at 
http://www.bio-add.org/ADRAlert/ or its mirror site at http://bioinf.xmu.edu.cn/ADRAlert/gene. 
We constructed the server upon a Linux + Tomcat architecture and developed interactive 
user-interfaces using JavaScript. The ADRAlert-gene could provide not only de novo assessment 
of drug safety but also the quantitative measure of gene-ADR relations. We described the details 
of ADRAlert-gene access in the Supplementary Information.
ToxicityScore is a suitable parameter for evaluating overall drug safety quantitatively
In this study, we introduced a novel parameter, the ToxicityScore, to summarize the overall drug 
safety in a broad spectrum of 1,156 distinct ADR HLTs. To evaluate the reliability of 
ToxicityScore in representing the overall drug safety, we made statistical analyses on the 
ToxicityScores of 432 selected drugs, covering 20 Over-the-Counter (OTC) drugs, 412 
prescription drugs, and 1,058 distinct known ADRs. The average ToxicityScore for the known 
ADRs of OTC drugs, determined by the observed ADR occurrence rate and the estimated ADR A
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frequency, were 45.19 and 56.41, respectively (Figure 1B&D). These values were comparatively 
smaller than those of the prescription drugs, which were 60.91 and 65.50 (Figure 1B&D), 
respectively. We also observed a significant difference in value ranges of ToxicityScores for drugs 
of different Anatomical Therapeutic Chemical (ATC) categories (Figure 1A&C). The ATC 
category system is formulated by WHO to divide the active substances into different categories 
according to the organ system on which they act and as well as their therapeutic, pharmacological 
and chemical properties. For instance, the antineoplastic and immunomodulation agents owned 
comparatively higher ToxicityScores (104.57 in average, determined by the observed ADR 
occurrence) than that of drugs in the category of alimentary tract and metabolism (21.15 in 
average). This finding indicates drug candidates with relatively high toxicity scores would still 
have the chance to enter the market if they meet the needs of critically ill patients. Moreover, we 
compared the ToxicityScores of the 432 selected drugs by ATC categories. We found the scores 
determined by either estimated or observed ADR frequency well correlated (R = 0.94, p < 10-6) 
(Figure 1A&C). This result partially proved the feasibility and reliability of ToxicityScore in the 
evaluation of drug safety. Therefore, the ToxicityScore of current marketed drugs can serve as a 
suitable reference for selecting “safe” drug candidates according to their indications in early drug 
discovery stage.
Example applications
Example 1: Identification of novel ADRs for known drugs
Lansoprazole is usually used to inhibit the acid production of stomach. Searching “lansoprazole” 
via the “From Drug” view responds eight signature genes from the LINCS Project (33-35) and 32 
lansoprazole-interacting genes from the CTD (32). Based on these regulated genes, the server 
predicted 368 ADRs for lansoprazole by the frequency threshold of 0.1%. The 368 predicted 
ADRs fully cover all 329 documented ADRs in drug label in the ADReCS database; the detection 
rate (DR) is 100%. Of note, the majority of 329 known ADRs have generally higher estimated 
frequency than those of the remaining 39 novel ADRs. Out of the 39 novel ADRs, we found 15 
ADRs, including heart failures, mental disorders, and non-site-specific injuries, in recent ADR 
collection of lansoprazole treatment in the Side Effect Resource (SIDER 4.1) (31), DailyMed A
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(updated by February 2017), and ClinicalTrials.gov database (by January 2019).
Example 2: De novo ADR assessment
Levosalbutamol is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma 
and chronic obstructive pulmonary disease (COPD). As of October 2019, levosalbutamol has been 
tested against asthma in phase III and IV clinical trials. As documented in the ClinicalTrials 
database, levosalbutamol might cause 71 different ADRs in 217 studies, covering a few hundreds 
of selected patients. As well, mining of the US FDA Adverse Event Reporting System (FAERS) 
(46) identified 114 potential levosalbutamol-ADR associations in 306 reports. Using seven 
levosalbutamol-regulated genes (RFC2, LOXL1, PCSK1N, BID, HOXA10, LSR, and HSPA4L) 
extracted from the LINCS (33-35), ADRAlert-gene predicted total 225 ADRs via the “From 
Gene” view at the frequency threshold of 0.1%. Of the 71 observed ADRs, 36 (about 50.70%) 
were predicted by the server with comparatively high frequency (3.84% averagely). For the 114 
possible levosalbutamol-induced ADRs mined from the FAERS, 72 (about 63.16%) were 
predicted by the server. The remaining 138 predicted ADRs were either novel ADRs haven’t been 
reported due to the limitation of trial data or potentially false positives. 
In real world, the clinical safety of a new molecular entity (NME) can be evaluated in a simple 
way of comparing the calculated ToxicityScore against that of the marketing drugs, especially the 
drugs of same indication (e.g., ATC category) (Figure 1). If the NME has a substantially higher 
ToxicityScore and consists of severe ADRs with estimated frequency >=0.1% particularly, further 
clinical trials should be prudentially conducted. In this example, the server evaluated 
levosalbutamol safety with a ToxicityScore of 60.870 at the frequency threshold of 0.1%. This 
score was much higher than that of the marketing drugs of the Respiratory System category, which 
is 18.78 in average. Two common (estimated frequency>=10%) severe ADRs ("cardiac signs and 
symptoms" and "circulatory collapse and shock") and a less common (estimated frequency of 
about 0.89%) life-threatening ADR "sepsis" may answer for the high ToxicityScore. These three 
severe ADRs have been reported in the ClinicalTrials and FAERS. Therefore, more attentions are 
expected to monitor levosalbutamol safety in clinical trials.
Example 3: Mechanistic understanding of ADRs by network analysis of gene-ADR associationsA
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Allergic conditions (ACs, ADReCS ID: 10.01.03) is a group of ADRs, including allergic 
reactions, hypersensitivity, asthma, Stevens-Johnson syndrome, and so on. Up to date, the 
molecular mechanisms underlying ACs have not yet been fully explored. By searching “Allergic 
conditions” or “10.01.03” via the “Gene-ADR From ADR” view, we extracted 8,571 
ACs-associated genes (3,852 up-regulated, 757 down-regulated, and 3,962 both up-regulated and 
down-regulated). We selected 563 comparatively strong AC-associated genes (the association 
strength >=0.025) for later mechanistic study. Of them, 424 were up-regulated genes and 139 were 
down-regulated genes. We mapped these 563 genes against the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway database (47, 48), which identified 209 ACs-associated pathways. Out 
of them, we specified 34 major ACs-associated pathways (covering at least six ACs-associated 
genes), of which about one-third (12 pathways) belong to the signal transduction pathways and 
immune system pathways (Figure 2A). The 209 ACs-associated pathways include total of 225 
ACs-associated genes. Eight of them (ALOX5, DNMT1, HLA-B, IFNG, IL15, ITGB2, KNG1 and 
TBXA2R) have literature evidence from the CTD (32) and the Online Mendelian Inheritance in 
Man (OMIM) (49) to support their associations with the allergy symptoms. In basis of the 225 
KEGG-mapped genes, we constructed a gene-gene interaction network (Figure 2B), from which 
we identified five hub genes (CXCL10, HUWE1, ITGB2, RPS23 and SELL) by satisfying the 
criteria of: owning a contion degree >=8 and neighboring to two or more known ACs-related 
genes. These hub genes are potential major gene players in understanding drug-induced allergic 
reactions. Of them, ITGB2 was previously reported to be a biomarker in monitoring the 
dysregulated allergic response (50). CXCL10 exhibited significantly higher concentration in 
allergic patients than that of the healthy subjects (51). The protein of HUWE1 might function as 
an E3 ubiquitin ligase that played a role in modulating allergic responses (52).
Discussion
This work introduces an advanced machine learning model and its web service ADRAlert-gene for 
rapid drug safety assessment via learning drug-gene-ADR complex network. Compared to prior 
methods, it has several advantages: (1) to our limited knowledge, ADRAlert-gene is the only A
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method that provides broad-spectrum ADR profiling. It allows reviewing the drug safety in a 
landscape of 1,156 distinct ADRs. (2) Unlike many target-based models that heavily rely on 
complete chemical-protein interaction profile for reliable ADR prediction, ADRAlert-gene just 
requests representative drug-gene regulation profile (i.e., significantly differentiated genes of drug 
treatment), which is easier to obtain via state-of-art transcriptome technology in nowadays 
practice. (3) The ADRAlert-gene is, up-to-date, the first tool that provides comprehensive 
information more than simple ADR prediction. The ToxicityScore integrates multiple information 
of ADR number, ADR frequency, and ADR severity quantitatively to measure overall drug safety. 
As we known, the high-incidence or severe ADRs usually receive more attentions in clinic and 
new drug discovery. (4) Last but not least, the ADRAlert-gene provides a new thought to reveal 
major gene players in ADR via genome-wide quantifying gene-ADR associations. Such kind of 
quantitative gene-ADR association profile is hard to obtain through conventional molecular 
technologies. 
We also acknowledge several limitations of the model. First, current version of ADRAlert-gene 
model was partially built upon drug-gene regulations derived from the LINCS project. 
Unfortunately, the experiment design and data quality of LINCS project is arguable itself since it 
was not particularly designed for drug toxicity research. Especially, most cells used in the LINCS 
project are tumor cell lines instead of primary normal cells in which most ADRs may occur. 
Secondly, the drug-treated transcriptomes determined on various cell lines are likely to be 
different from those of individual patients; even though, recent research suggested that the 
transcriptomes on human cell lines could honestly reflect human response (53). Thirdly, the 
drug-gene relations mined from heterogeneous cell transcriptomes are not always consistent, 
pending to the improvement of data analysis and new technology. Last but not least, the model 
was developed in basis of monotherapy assumption. In reality, most patients are typically on 
polypharmacy regiment, which sometimes confronts the ADRs caused by drug-drug interactions. 
The drug-drug interactions are so complex that they are hard to be quantified and implemented 
into this model by now. Therein, multiple factors may take part in the ADRs caused by the 
drug-drug interactions, including the combination of drug dosages, the order and the interval of A
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polypharmacy treatment, the administration routes of drugs, and so on. More efforts are expected 
to improve the model in the future.
Nevertheless, ADRAlert-gene can serve as a powerful, practical, and economical tool for drug 
safety profiling. It helps to reduce the attrition rate of new drug discovery by offering reliable 
ADR profile in early pre-clinical stage. It also provides a shortcut for network understanding of 
molecular mechanisms underlying ADRs. In particular, the identification of ADR-associated 
genes allows targeting the potential molecular causes of ADR directly. This could accelerate 
precision medicine since genetic testing would build the pharmacogenetic profile of different 
patients’ responses to the same drug quickly and undistractedly. Therefore, we believe that 
ADRAlert-gene will benefit the communities of both clinical pharmacology and toxicology. It will 
be especially useful for drug design, ADR mechanism study and individual drug therapy.
Study Highlights
- What is the current knowledge on the topic?
The adverse drug reaction (ADR) is a severe clinical pharmacology/toxicology problem that has 
caused immense medical and social burdens. It is also one of the two major causes leading to new 
drug discovery failure. Unfortunately, current mechanistic understanding and profiling of drug 
safety are still limited in both concept and methodology. 
- What question does this study address?
Most of current experimental and computational methods primarily focus on drug toxicity in cell 
or tissue/organ instead of adverse consequence in clinic. Furthermore, there still misses a general 
and reproducible method for exploring ADR mechanisms systematically.
- What this study adds to our knowledge
This study implements a new method for broad-spectrum ADR profiling. It suggests a gene-based 
systematic exploration of ADR mechanism, which is applicable to most ADRs.
- How this might change clinical pharmacology or translational science?
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This study provides new insights to understand clinical pharmacology. This study may enhance 
the success rate of new drug discovery by reducing the drug safety problems in clinical trials. It 
also helps prioritize clinical pharmacogenetic tests for safe drug therapy. 
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Figure legends
Figure 1. Statistics of ToxicityScores by drug types.
The ToxicityScores of different ATC drug types, determined by the observed occurrence rate (A) 
and the estimated occurrence rate (C) of known ADRs, respectively. The ToxicityScores of 20 
OTC drugs and 412 prescription drugs, determined by the observed occurrence rate (B) and the 
estimated occurrence rate (D) of known ADRs, respectively. The color box stands for 75% of data, 
the black line stands for the median value, and the asterisk stands for the mean value.
Figure 2. Mechanistic understanding of allergic conditions (ACs, ADReCS ID: 10.01.03).
(A) The KEGG pathways associated with allergic conditions. The number of genes mapped into 
each of these pathways are given in the parenthesis. (B) The allergic conditions associated gene 
interaction network, constructed by the GeneMANIA CytoScape plugin. The green circles and the 
orange circles stand for the ACs-associated genes identified in this study and the known gene 
markers of ACs, respectively. The node size is positively proportional to the connectivity degree 
of node, and the width of edge stands for the weight of gene-gene interaction. This network 
consists of 89 genes and 127 gene-gene interactions with weight > 0.001.
Figure 3. The hypothesis of broad-spectrum ADR assessment via solving multilayer 
drug-gene-ADR interaction network. 
We made the drug safety profiling by statistically solving the multilayer drug-gene-ADR 
interaction network in basis of hypothesis as following: ADRs sometimes happen during drug 
treatment. The adverse effects are the integrated results of multiple mechanism-of-actions (MOAs) 
such as overdose, weak pharmacokinetics, unexpected drug-drug interaction, off-target interaction, 
and so on. Beneath, the MOAs could be driven by abnormality of proteins, disturbance of 
pathways, dysfunction of organs, and so on. In most cases, the exact mechanisms are hard to be 
determined by current experimental or computational methods. However, genes change 
expressions as the biological outcome in response to drug treatment at the same time. There surely A
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exists some association between gene expression change and ADR occurrence. In basis of this, we 
bypass the exact MOAs, leaving them as a black box; alternatively, we link gene expression 
perturbations to ADRs directly via machine learning the complex drug-gene-ADR trilateral 
relationship. 
Figure 4. The model performance by number of drug-gene regulations.
(A) The average detection rates (DRs) and the “false positive” rates (FPRs) (above frequency 
threshold of 1%) change along with the number of drug-gene relations used in model prediction. 
(B) The model performance evaluated by the receiver operating characteristic (ROC) curve using 
both the internal and external dataset.
Supplementary Materials
Text: Supplementary Information.docx
Figure: Supplementary Figure S1.tif
Table: Table S1.doc
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved 
Table 1. Performance of the advanced machine learning model 
Model 
Internal validation (n = 365) External validation (n = 18) 
Frequency>0 Frequency≥0.1% 
Frequency>0 Frequency≥0.1% 
Accuracy 52.54% 81.11% 34.50% 75.59% 
Sensitivity 90.00% 70.62% 96.41% 76.44% 
Specificity 48.78% 82.17% 25.98% 75.47% 
AUC 82.71% 78.91% 82.83% 79.85% 
Average DR 91.70% 75.10% 98.22% 84.38% 
Average FPR 51.04% 17.56% 73.76% 23.99% 
DR: detection rate; FPR: false positive rate 
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